Tenfold bull stocks received a regulatory letter.
Andon Health Co.Ltd(002432) it was disclosed in the morning today (February 22) that the regulatory letter of Shenzhen Stock Exchange was received due to the inaccurate and incomplete Reply of the investor platform for many times.
In early trading today, Andon Health Co.Ltd(002432) fell 4.54% to 69.78 yuan / share, and its covid-19 detection sector fell more than 3%.
In addition, Aba Chemicals Corporation(300261) , Beijing Hotgen Biotech Co.Ltd(688068) , Hybio Pharmaceutical Co.Ltd(300199) and other covid-19 drug concept stocks had a significant correction.
Similarly, due to incomplete information disclosure, previously Andon Health Co.Ltd(002432) had received the decision on administrative supervision measures. In addition, Liu Yi, as the chairman and general manager of Andon Health Co.Ltd(002432) , and Wu Tong, as the Secretary of Andon Health Co.Ltd(002432) , bear the main responsibility for the integrity of the information disclosure of the interim report. As a result, the two were taken regulatory measures by Tianjin Securities Regulatory Bureau.
the letter Phi has been inaccurate and incomplete for many times
Since the covid-19 antigen home self-test kit was authorized by the United States for emergency use in November last year, Andon Health Co.Ltd(002432) has quickly become a star company in the market.
On the secondary market, Andon Health Co.Ltd(002432) share price took off. Since the middle of November last year, the stock has achieved 33 trading limits. Although it has retreated recently, it still increased nearly 10 times during the period. Whether it is the limit or the range increase, Andon Health Co.Ltd(002432) is far ahead of all A-share companies.
At the same time, Andon Health Co.Ltd(002432) has responded to investors’ concerns through interactive platforms for many times, further catalyzing the enthusiasm of the market. With the soaring share price, in the past three months, the company has successively received five attention letters or supervision letters around the covid-19 antigen home self-test kit business, and the supervision attention has become “commonplace”.
The latest regulatory letter and the previous decision on administrative regulatory measures mainly focused on the experimental report disclosed by Andon Health Co.Ltd(002432) at the beginning of this year.
On January 7, Andon Health Co.Ltd(002432) disclosed that on January 5, 2022 Beijing time, the company received the performance test report of the Radx project of the National Institutes of Health (NIH) on the ihealth covid-19 antigen home self-test OTC kit against Omicron variant virus arranged by the FDA.
The supervision letter of Shenzhen Stock Exchange pointed out that the report showed that 100% of the samples of Omicron active virus with a maximum CT value of 21.59 (n = 5) were detected by ihealth kit in the experiment. On January 15, 2022, when replying to the letter of concern, the company said that “the positive detection rate of all samples in the experimental group: when the CT value is ≤ 21.59, it can be detected completely, when the CT value is 22.86, it can be detected 60%, and when the CT value is ≥ 23.87, it can not be detected at all”. The information disclosure of the experimental results in the announcement of the company on January 7, 2022 is incomplete.
In addition, Andon Health Co.Ltd(002432) the reply of the alleged investor platform has been inaccurate and incomplete for many times.
According to the regulatory letter, on December 1, 2021, Andon Health Co.Ltd(002432) said in response to investors’ questions on the interactive easy platform, “up to now, our covid-19 test reagent ranks first in the sales of Amazon’s website in the United States”. On December 29, 2021, when replying to the attention letter, the company said, “Amazon America’s sales ranking is a comprehensive ranking based on the combination of daily sales and instantaneous sales, and the ranking will be updated in real time, which does not represent the cumulative sales”.
On December 21, 2021, the company replied to investors’ questions about the product quality reflected by Amazon American consumers on the interactive platform, “although the sales volume of our kit in Amazon America is very small”, and then corrected it to “although the number of quality feedback problems of this product in Amazon America accounts for a small proportion of Amazon American sales volume” on December 22, 2021, The contents and meanings of the statements before and after correction are quite different.
On December 30, 2021, the company stated in the record of investor relations activities published on the interactive easy platform that ” Andon Health Co.Ltd(002432) holds 80% of the shares of ihealth USA, the main seller of test kits”. After the post review and supervision of the management department of listed companies on Shenzhen Stock Exchange, the company corrected it to ” Andon Health Co.Ltd(002432) holds 70.46% of the shares of ihealth USA, the main seller of test kits”.
In December 2021, the company’s share price increased by 161.34% in total, and the abnormal fluctuation standard of stock trading was touched five times during the period. During the continuous stock price changes, the company’s reply on the interactive trading platform and the record form of investor relations activities published by the company have been inaccurate and incomplete for many times.
It is noteworthy that behind the take-off of the stock price, Andon Health Co.Ltd(002432) also benefited significantly from covid-19 kit products.
Andon Health Co.Ltd(002432) previously, it was predicted that the net profit in 2021 would be the highest or nearly quadrupled, and the annual profit was expected to be RMB 900 million to RMB 1.2 billion. The sharp increase in the company’s performance was mainly due to the significant increase in the sales of covid-19 antigen home self-test products in the U.S. market at the end of last year. The single quarter profit of Andon Health Co.Ltd(002432) in the fourth quarter is expected to be about RMB 850 million to RMB 1.15 billion, exceeding the total net profit of each year since its listing in 2010.
However, Andon Health Co.Ltd(002432) also indicated in the performance forecast that the company’s operating performance in 2021 mainly depends on covid-19 testing reagent. There are major uncertainties whether the future performance can continue to maintain rapid growth, which mainly depends on the progress of covid-19 epidemic prevention and control in the United States, the selection of covid-19 testing products in the United States, the market competitiveness of the company’s products and channel sales ability, And the future development of conventional business.
Niugu concentration camp has become the focus of attention letters
Not only the leader Andon Health Co.Ltd(002432) , covid-19 concept stocks have become the focus of regulatory attention letters.
According to incomplete statistics, since the beginning of the year of the tiger alone, many covid-19 concept stocks such as Aba Chemicals Corporation(300261) , Porton Pharma Solutions Ltd(300363) , Chengda pharmaceutical, Hybio Pharmaceutical Co.Ltd(300199) , Honz Pharmaceutical Co.Ltd(300086) , Shanxi C&Y Pharmaceutical Group Co.Ltd(300254) , Nanjing Hicin Pharmaceutical Co.Ltd(300584) have received regulatory attention letters.
In particular, after Pfizer’s covid-19 oral drug was urgently approved by China on February 11, the relevant covid-19 concept stocks changed significantly and were targeted by regulators.
For example, the increase in recent three months is only inferior to Andon Health Co.Ltd(002432) ‘s “covid-19 specific drug concept stock” Aba Chemicals Corporation(300261) . The stock also rose continuously since November last year, during which the share price rose nearly four times.
On February 14, Aba Chemicals Corporation(300261) received a letter of concern from the Shenzhen Stock Exchange. The letter pointed out that recently, some investors inquired about the relevant information of Aba Chemicals Corporation(300261) approved new projects with an annual output of 50 tons of parovid API products in the interactive platform of the exchange. Some investors mentioned in their complaints to the company that the company has applied for the project with an annual output of 50 tons of parovid API and 500 tons of caronic anhydride intermediates 300 tons of azabicyclohydrane and other projects have been approved, but the company did not disclose the relevant information.
On February 14, Aba Chemicals Corporation(300261) share price rose by the limit. In this regard, Shenzhen stock exchange requires Aba Chemicals Corporation(300261) in combination with the specific situation of the project, to explain the reasons why the project name involves palovide API, Caron anhydride intermediate and azabicyclohexane, and whether it is related to Pfizer covid-19 oral drug palovide. If so, explain the specific relevance and judgment basis. At the same time, in combination with the above reply, explain whether the project declared by the company belongs to the major information that should be disclosed in accordance with the relevant provisions of Shenzhen Stock Exchange, whether there is any undisclosed situation that should be disclosed, and whether there is any situation that the project declaration is used to cater to the hot spots of the market.
On the secondary market, Aba Chemicals Corporation(300261) shares hit another record high yesterday. In early trading today, Aba Chemicals Corporation(300261) shares fell back from a high, down 7.7% to 26.96 yuan / share, with a current market value of about 26 billion yuan.
Yesterday, Aba Chemicals Corporation(300261) also released the announcement of abnormal stock fluctuation again. The company stressed again that it had not signed a cooperation agreement with Pfizer, supplied carlon anhydride products to Pfizer, and Pfizer had not provided the company with any quality standards for the purchase of covid-19 oral front-end raw materials, And the company’s customers refuse to provide the end use of the purchasing company’s carbonic anhydride and its derivatives.
